公开(公告)号：US11224611B2

公开(公告)日：2022-01-18

申请号：US17076677

申请日：2020-10-21

Applicant: IDERA PHARMACEUTICALS, INC.

Inventor： Sudhir Agrawal ,  Daqing Wang ,  Wayne Jiang

IPC: A61K31/713 ,  A61K45/06 ,  A61P35/04 ,  A61P35/00 ,  A61K39/395 ,  C07K16/28 ,  A61K9/00

Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.

公开(公告)号：US10772907B2

公开(公告)日：2020-09-15

申请号：US16557630

申请日：2019-08-30

Applicant: IDERA PHARMACEUTICALS, INC.

Inventor： Sudhir Agrawal ,  Daqing Wang ,  Wayne Jiang

IPC: C07H21/04 ,  A61K31/713 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K45/06 ,  A61P35/04 ,  A61K9/00

Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.

公开(公告)号：US20180044669A1

公开(公告)日：2018-02-15

申请号：US15794643

申请日：2017-10-26

Applicant: IDERA PHARMACEUTICALS, INC.

Inventor： Sudhir AGRAWAL ,  Wayne JIANG ,  Daqing Wang ,  Jessica Seitzer ,  Fu-Gang Zhu ,  Xianzhi Mao

IPC: C12N15/11 ,  A61K31/7105 ,  C12N15/113 ,  A61K45/06

CPC classification number: C12N15/11 ,  A61K31/7105 ,  A61K45/06 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/314 ,  C12N2310/51

Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5′-ends to allow the presence of two or more accessible 3′-ends.

公开(公告)号：US20170233741A1

公开(公告)日：2017-08-17

申请号：US15366509

申请日：2016-12-01

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Ekambar R. Kandimalla ,  Daqing Wang ,  Ireneusz Nowak ,  Sudhir Agrawal

IPC: C12N15/117 ,  A61K45/06 ,  A61K31/7125

CPC classification number: C12N15/117 ,  A61K31/7115 ,  A61K31/7125 ,  A61K45/06 ,  C12N2310/17 ,  C12N2310/31 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/336 ,  C12N2310/51 ,  C12N2310/52 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/414 ,  A61K2300/00

Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

公开(公告)号：US10041076B2

公开(公告)日：2018-08-07

申请号：US15209333

申请日：2016-07-13

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Ekambar R. Kandimalla ,  Daqing Wang ,  Dong Yu ,  Ireneusz Nowak ,  Sudhir Agrawal

IPC: A61K39/39 ,  A61K45/06 ,  C12N15/117 ,  A61K9/00 ,  A61K31/711 ,  A61K31/7115 ,  A61K39/00

Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

公开(公告)号：US09828601B2

公开(公告)日：2017-11-28

申请号：US15053309

申请日：2016-02-25

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Sudhir Agrawal ,  Wayne Jiang ,  Daqing Wang ,  Jessica Seitzer ,  Fu-Gang Zhu ,  Xianzhi Mao

IPC: C07H21/04 ,  C12N15/11 ,  A61K31/7105 ,  A61K45/06 ,  C12N15/113

CPC classification number: C12N15/11 ,  A61K31/7105 ,  A61K45/06 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/314 ,  C12N2310/51

Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5′-ends to allow the presence of two or more accessible 3′-ends.

公开(公告)号：US09243050B2

公开(公告)日：2016-01-26

申请号：US14284938

申请日：2014-05-22

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Ekambar R. Kandimalla ,  Tao Lan ,  Yukui Li ,  Dong Yu ,  Daqing Wang ,  Mallikarjuna Putta ,  Sudhir Agrawal

IPC: A61K48/00 ,  C07K14/665 ,  C12N15/117 ,  A61K39/00 ,  A61K39/395 ,  A61K31/713

CPC classification number: C07K14/665 ,  A61K31/713 ,  A61K39/0005 ,  A61K39/395 ,  A61K39/3955 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/315 ,  C12N2310/318 ,  C12N2310/3183 ,  C12N2310/321 ,  C12N2310/33 ,  C12N2310/331 ,  C12N2310/336 ,  C12N2310/3521

Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.

Abstract translation: 本发明涉及稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。 具体地，本发明提供具有改进的核酸酶和核糖核酸酶稳定性的基于RNA的寡核糖核苷酸，并且通过TLR7和/或TLR8具有免疫调节活性。

公开(公告)号：US20140308300A1

公开(公告)日：2014-10-16

申请号：US14284938

申请日：2014-05-22

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Ekambar R. Kandimalla ,  Tao Lan ,  Yukui Li ,  Dong Yu ,  Daqing Wang ,  Mallikarjuna Putta ,  Sudhir Agrawal

IPC: C07K14/665 ,  A61K39/395 ,  A61K39/00 ,  A61K31/713

CPC classification number: C07K14/665 ,  A61K31/713 ,  A61K39/0005 ,  A61K39/395 ,  A61K39/3955 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/315 ,  C12N2310/318 ,  C12N2310/3183 ,  C12N2310/321 ,  C12N2310/33 ,  C12N2310/331 ,  C12N2310/336 ,  C12N2310/3521

Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.

Abstract translation: 本发明涉及稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。 具体地，本发明提供具有改进的核酸酶和核糖核酸酶稳定性的基于RNA的寡核糖核苷酸，并且通过TLR7和/或TLR8具有免疫调节活性。

公开(公告)号：US09540651B2

公开(公告)日：2017-01-10

申请号：US14791749

申请日：2015-07-06

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Ekambar R. Kandimalla ,  Daqing Wang ,  Ireneusz Nowak ,  Sudhir Agrawal

IPC: A61K31/7115 ,  C12N15/117 ,  A61K45/06

CPC classification number: C12N15/117 ,  A61K31/7115 ,  A61K31/7125 ,  A61K45/06 ,  C12N2310/17 ,  C12N2310/31 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/336 ,  C12N2310/51 ,  C12N2310/52 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/414 ,  A61K2300/00

Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

Abstract translation: 本发明提供作为TLR拮抗剂的新型免疫调节寡核苷酸（IRO）及其使用方法。 这些IRO具有独特的序列，其响应于TLR配体或TLR激动剂抑制或抑制TLR介导的信号传导。 该方法可用于预防和治疗癌症，自身免疫性疾病，气道炎症，炎症性疾病，感染性疾病，皮肤病，变态反应，哮喘或由病原体引起的疾病。

公开(公告)号：US20160215287A1

公开(公告)日：2016-07-28

申请号：US14791749

申请日：2015-07-06

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Ekambar R. Kandimalla ,  Daqing Wang ,  Ireneusz Nowak ,  Sudhir Agrawal

IPC: C12N15/117 ,  A61K45/06 ,  A61K31/7115

CPC classification number: C12N15/117 ,  A61K31/7115 ,  A61K31/7125 ,  A61K45/06 ,  C12N2310/17 ,  C12N2310/31 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/336 ,  C12N2310/51 ,  C12N2310/52 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/414 ,  A61K2300/00

Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.